Novavax: differenze tra le versioni
Contenuto cancellato Contenuto aggiunto
Riga 44:
===Candidato al vaccino contro il COVID-19===
{{vedi anche| Vaccino anti COVID-19 Novavax}}
Nel gennaio 2020, Novavax ha annunciato lo sviluppo di un candidato [[vaccino]], denominato NVX-CoV2373, per stabilire l'[[Sistema immunitario|immunità]] dall’[[infezione]] di [[SARS-CoV-2]].<ref name="gilgore">{{cite news |author1=Sara Gilgore |title=Novavax is working to advance a potential coronavirus vaccine. So are competitors.|url=https://www.bizjournals.com/washington/news/2020/02/26/novavax-is-moving-forward-with-a.html |work=Washington Business Journal |access-date=6 March 2020 |date=26 February 2020 |archive-date=16 March 2020 |archive-url=https://web.archive.org/web/20200316041227/https://www.bizjournals.com/washington/news/2020/02/26/novavax-is-moving-forward-with-a.html |url-status=live }}</ref>
NVX-CoV2373 è un vaccino a [[subunità]] proteica che contiene la [[proteina]] [[Peplomero|spike]] del [[virus]] SARS-CoV-2.<ref name="Novavax">{{cite news |author1=Nidhi Parekh |title=Novavax: A SARS-CoV-2 Protein Factory to Beat COVID-19. |url=https://fancycomma.com/2020/07/24/novavax-protein-subunit-covid-19-vaccine/ |access-date=24 July 2020 |date=24 July 2020 |archive-date=22 November 2020 |archive-url=https://web.archive.org/web/20201122040118/https://fancycomma.com/2020/07/24/novavax-protein-subunit-covid-19-vaccine/ |url-status=live }}</ref> Novavax si trova quindi, da questo momento, in competizione per lo sviluppo del vaccino tra dozzine di altre aziende farmaceutiche.
| |||